Table 2.
Serum pro-inflammatory cytokine Levels amongst HIV infected subjects before commencement of HAART, 6 months into HAART and 1 year into HAART (±SD)
| Group | IL-6 (Pg/ml) | INF-γ (Pg/ml) | TNF-α (Pg/ml) |
|---|---|---|---|
| Before commencement of HAART {a} (n = 50) | 18.34 ± 5.83 | 0.78 ± 0.06 | 41.32 ± 12.99 |
| 6 Months into HAART{b} (n = 50) | 10.43 ± 4.98 | 2.25 ± 0.91 | 29.32 ± 10.51 |
| 1 Year into HAART{c} (n = 50) | 7.05 ± 3.43 | 2.64 ± 0.96 | 15.98 ± 4.81 |
| Control {d} (n = 50) | 4.62 ± 1.04 | 4.89 ± 0.23 | 9.40 ± 3.52 |
| F Value | 60.90 | 11.37 | 75.62 |
| P Value | 0.00 | 0.02 | 0.00 |
| {a} Vs {b} | P < 0.05 | P < 0.05 | P < 0.05 |
| {a} Vs {c} | P < 0.05 | P < 0.05 | P < 0.05 |
| {a} Vs {d} | P < 0.05 | P < 0.05 | P < 0.05 |
| {b} Vs {c} | P < 0.05 | P < 0.05 | P < 0.05 |
| {b} Vs {d} | P > 0.05 | P < 0.05 | P < 0.05 |
| {c} Vs {d} | P > 0.05 | P < 0.05 | P < 0.05 |
IL-6 Interleukin 6, INF-γ Interferon Gamma, TNF-α Tumour Necrosis Factor alpha, Vs Versus, HAART Highly Active Antiretroviral Therapy, n number of participants